Side effects not a major problem for new class of breast cancer drugs

(Wiley) A ground-breaking new class of oral drugs for treating breast cancer, known as cyclin-dependent kinase (CDK) inhibitors, are generally well-tolerated, with a manageable toxicity profile for most patients.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Clinical Significance of Human Papillomavirus Type 16 for Breast Cancer &Adenocarcinomas of Various Internal Organs and Alzheimer's Brain with Increased β-amyloid (1-42); Combined Use of Optimal Doses of Vitamin D3 and Taurine 3 times/day Has Significant Beneficial Effects of Anti-Cancer, Anti-Ischemic Heart, and Memory &Other Brain Problems By Significant Urinary Excretion of Viruses, Bacteria, and Toxic Metals &Substances. Acupunct Electrother Res. 2016;41(2):127-134 Authors: Omura Y Abstract Human Papillomavirus type 16 (HPV-16) has a significant role in various cancers and Alzheime...
Source: Acupuncture and Electro-Therapeutics Research - Category: Complementary Medicine Tags: Acupunct Electrother Res Source Type: research
CONCLUSION: Metronomically administered oral vinorelbine, either as monotherapy or in combination with other drugs, is effective in the long-term treatment of patients with advanced breast cancer. The clinical profiles of patients should be carefully considered to determine the appropriate treatment strategy. PMID: 29902087 [PubMed - as supplied by publisher]
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Abstract Background: The CDK4/6 inhibitor Palbociclib is a new standard treatment in hormone-receptor positive breast cancer patients. No predictive biomarkers have been identified and no pharmacodynamics has properly been described so far. Patients and methods: Patients with early breast cancer were randomized 3:1 to oral palbociclib 125mg daily for 14 days until the day before the surgery vs. no treatment. Primary objective was antiproliferative response defined as a natural logarithm of Ki67 expression at day 15 below 1. Secondary end-points were subgroups analyses and safety. Exploratory analyses included...
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Oncol Source Type: research
SummaryUp-regulation of the Hedgehog (Hh) pathway is implicated in the genesis of a wide range of tumors including triple negative breast cancer (TNBC). Sonidegib is a potent and selective oral inhibitor of Smo, a key component of the Hh signaling pathway. We designed a phase I clinical study to explore the combination of sonidegib plus docetaxel (fixed dose at 75  mg/m2) in advanced TNBC patients. The primary objective was to ascertain the combination ’s maximum tolerated dose and the recommended phase II dose (RP2D), based on dose limiting toxicities (DLTs) in the first 2 cycles. A standard “3&thins...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
In this study, we investigated whether Bcl-2 inhibition could sensitize TNBC cells to the genotoxic drug doxorubicin (DR). Treatment with a combination of the Bcl-2 inhibitor ABT-199 and DR synergistically decreased the viability of the TNBC cell lines MDA-MB-231 and BT-549. In an apoptosis assay, the combination treatment resulted in only a marginal effect in BT-549 cells, whereas drastic apoptosis was induced in MDA-MB-231 cells treated with both ABT-199 and DR. Both caspase-8 and -9 were involved in the combination treatment-induced apoptosis. Short interfering RNA-mediated knockdown of Bcl-2 increased the sensitivity o...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Grauzam S, Brock AM, Holmes CO, Tiedeken JA, Boniface SG, Pierson BN, Patterson DG, Coaxum SD, Neskey DM, Rosenzweig SA Abstract Neural precursor cell expressed developmentally downregulated 9 (NEDD9) is a component of the metastatic signatures of melanoma, breast cancer, glioblastoma, lung cancer and head and neck squamous cell carcinoma (HNSCC). Here we tested the efficacy of NEDD9's domains in stimulating matrix metalloproteinase (MMP) secretion and invadopodia formation in cells stably expressing various NEDD9 mutants. Replacement of the 13 YxxP motif substrate domain (SD) tyrosines and the C-terminal ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
ConclusionsThe MTD of BEZ235 as single agent was 1200 and 600  mg/day with trastuzumab. Pharmacokinetic profiles showed low-to-moderate variability at low dose (10 mg) and high variability at high doses (100 mg and above). Gastrointestinal AEs were frequent at high doses.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
by Drew RosielleTheAmerican Society of Clinical Oncology annual meeting, besides being a feast for the pharmaceutical business news pages (google'ASCO'and most of the hits will be about how announcement X affected drug company Y's stock), is also one of the premiere platforms for publishing original palliative-oncology research. So every year I try to at least scan the abstracts to see what's happening, and I figure I might as well blog about it. It's tough to analyze abstracts, so I'll mostly just be summarizing ones that I think will be of interest to hospice and palliative care folks. I imagine I've missed some good one...
Source: Pallimed: A Hospice and Palliative Medicine Blog - Category: Palliative Care Tags: artificial nutrition ASCO cannabanoid code status conference reviews fatigue hpmglobal marijuana mindfulness mucositis neuropathic oncology pain race rosielle scrambler Source Type: blogs
(University of Texas M. D. Anderson Cancer Center) In a small Phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers at The University of Texas MD Anderson Cancer Center found that more than half of the women who took the PARP inhibitor talazoparib once daily prior to surgery had no evidence of disease at the time of surgery. If further validated in larger, confirmatory trials, the oral medication could replace chemotherapy for these patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2‑positive breast cancer. Mol Med Rep. 2018 May 23;: Authors: Matsumoto A, Hayashida T, Takahashi M, Jinno H, Kitagawa Y Abstract The human epidermal growth factor receptor 2 (HER2)‑targeting agent, lapatinib, combined with oral fluoropyrimidine capecitabine, has been previously demonstrated to be an effective treatment option for patients with trastuzumab‑resistant HER2‑positive metastatic breast cancer. To investigate the molecular mechanisms associated with the interactions between lapatinib and capecitabine...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Oral Cancer | Toxicology